The Labcorp Oncology team presents groundbreaking research during ASCO

The Labcorp Oncology Medical Affairs team presented groundbreaking research during the American Society of Clinical Oncology (ASCO) annual meeting held June 2-6 in Chicago, Illinois. This event brings together renowned oncology leaders, scientists and experts from around the globe to discuss the latest advancements in cancer research and treatment. 

Our dedicated team covered a range of topics including the following:

Comprehensive Genomic Profiling – Required Testing for Patients with Advanced Cancer: In the presentation, first author, Senior Director, Clinical Evidence Development, Oncology, Mary Nesline showed that negative single gene testing (SGT) for patients with non-small cell lung cancer done prior to comprehensive genomic profiling (CGP) doubled subsequent CGP test cancelations because of tissue insufficiency and increased CGP DNA extraction failures.  For patients with non-small cell lung cancer, tissue samples for testing are usually obtained by small biopsies. The standard of care for all patients with non-small cell lung cancer is to evaluate for >10 biomarkers so oncologists can recommend targeted, personalized therapies. If only single gene tests are ordered, then it is unlikely that patient will have all biomarkers tested and they may not be able to get a second biopsy for comprehensive testing. Furthermore, doing single gene tests before comprehensive profiling creates longer wait times for results—and this can be problematic when selecting optimal treatment for patients with cancer.

ASCO featured our work in their Daily News and in their podcast. 

View full abstracts